Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine after PCI for autonomic nervous function in coronary heart disease
ChiCTR1800017008Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trimetazidine in coronary arteriosclerosis (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: Heart rate variability and Serum catecholamine concentration. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
trimetazidine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800017008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017008.